# Safety and Efficacy of Exosomes Overexpressing CD24 in Two Doses for Patients With Moderate or Severe COVID-19

> **NCT04902183** · PHASE2 · UNKNOWN · sponsor: **Athens Medical Society** · enrollment: 90 (estimated)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** CovenD24

## Key facts

- **NCT ID:** NCT04902183
- **Lead sponsor:** Athens Medical Society
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-09
- **Primary completion:** 2021-09-01
- **Final completion:** 2021-09-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2021-06-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04902183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04902183, "Safety and Efficacy of Exosomes Overexpressing CD24 in Two Doses for Patients With Moderate or Severe COVID-19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04902183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*